Purification and chemical modifications of hemoglobin in developing hemoglobin based oxygen carriers

Advanced Drug Delivery Reviews

Volumn 40, Issue 3, 2000, Pages 153-169

  Haney, Chad R ^b   Buehler, Paul W ^a   Gulati, Anil ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b University of Illinois at Chicago   (United States)

Author keywords

Blood substitutes; Cross linking; Hypertensive drug effects; Polymerization

Indexed keywords

BLOOD SUBSTITUTES; CHEMICAL MODIFICATION; CROSSLINKING; POLYMERIZATION; PURIFICATION; TOXICITY;

HEMOGLOBIN BASED OXYGEN CARRIER; HYPERTENSIVE DRUG EFFECTS; RED BLOOD CELLS;

HEMOGLOBIN;

BLOOD SUBSTITUTE; HEMOGLOBIN DERIVATIVE;

ANIMAL CELL; CATTLE; CELL LYSATE; CHEMICAL MODIFICATION; CHROMATOGRAPHY; CONJUGATION; DIALYSIS; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; ERYTHROCYTE; HUMAN; HUMAN CELL; HYPERTENSION; MOLECULAR WEIGHT; NONHUMAN; OXYGEN AFFINITY; OXYGEN TRANSPORT; PASTEURIZATION; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN PURIFICATION; RECOMBINANT DNA TECHNOLOGY; REVIEW; TECHNIQUE; ULTRAFILTRATION; VASOCONSTRICTION; VISCOSITY;

EID: 0343852148     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00047-2     Document Type: Article

References (94)

1. Amberson W.R., Flexner J., Steggerda F.R., Mulder, Tendler M.J., Pankrantz D.S., Laug E.P. On the use of Ringer-Locke solution containing hemoglobin as a substitute for normal blood in mammals. J. Cell Comp. Physiol. 5:1934;359-382.
2. Rabiner S.F., Helbert J.R., Lopas H., Friedman L.H. Evaluation of a stroma-free hemoglobin solution for use as a plasma expander. J. Exp. Med. 126:1967;1127-1142.
3. Savitsky J.P., Doczi J., Black J., Arnold J.D. A clinical safety trial of stroma-free hemoglobin. Clin. Pharmacol. Ther. 23:1978;73-80.
4. Keipert P.E., Gomez C.L., Gonzales A., Macdonald V.W., Winslow R.M. The role of the kidneys in the excretion of chemically modified hemoglobins. Biomater. Artif. Cells Immobil. Biotechnol. 20:1992;737-745.
5. Riggs A. Preparation of blood hemoglobins of vertebrates. Methods Enzymol. 76:1981;5-29.
6. Marini M.A., Moore G.L., Christensen S.M., Fishman R.M., Jessee R.G., Medina F., Snell S.M., Zegna A.I. Re-examination of the polymerization of pyridoxylated hemoglobin with glutaraldehyde. Biopolymers. 29:1990;871-882.
7. Christensen S.M., Marini M.A., Zegna A., Snell S.M., Winslow R.M., Medina F. Preparation of human hemoglobin Ao for possible use as a blood substitute. J. Biochem. Biophys. Methods. 17:1988;143-154.
8. Dozy A.M., Kleihauer E.F., Huisman T.H. Studies on the heterogeneity of hemoglobin. 13. Chromatography of various human and animal hemoglobin types on DEAE-Sephadex. J. Chromatogr. 32:1968;723-727.
9. Huisman T.H., Dozy A.M. Studies on the heterogeneity of hemoglobin. IX. The use of tris(hydroxymethyl)aminomethane-HCl buffers in the anion-exchange chromatography of hemoglobins. J. Chromatogr. 19:1965;160-169.
10. DiDonato A., Fantl W.J., Acharya A.S., Manning J.M. Selective carboxymethylation of the alpha-amino groups of hemoglobin. Effect on functional properties. J. Biol. Chem. 258:1983;11890-11895.
11. Winslow R.M., Chapman K.W. Pilot-scale preparation of hemoglobin solutions. Methods Enzymol. 231:1994;3-16.
12. Williams R.C. Jr., Tsay K.Y. A convenient chromatographic method for the preparation of human hemoglobin. Anal. Biochem. 54:1973;137-145.
13. Sheffield C.L., Spates G.E., Droleskey R.E., Green R., DeLoach J.R. Preparation of lipid-free human hemoglobin by dialysis and ultrafiltration. Biotechnol. Appl. Biochem. 9:1987;230-238.
14. J.C. Hsia, Pasteurizable, freeze-driable hemoglobin-based blood substitute, U.S. Pat. No. 4,857,636, 1989.
15. Bucci E., Razynska A., Kwansa H., Matheson-Urbaitis B., O'Hearne M., Ulatowski J.A., Koehler R.C. Production and characteristics of an infusible oxygen-carrying fluid based on hemoglobin intramolecularly cross-linked with sebacic acid [see comments]. J. Lab. Clin. Med. 128:1996;146-153.
16. J. Everse, K.D. Vandegriff, R.M. Winslow, Hemoglobins. Academic Press, San Diego, 1994, pp. 743.
17. Fronticelli C., Bucci E., Orth C. Solvent regulation of oxygen affinity in hemoglobin. Sensitivity of bovine hemoglobin to chloride ions. J. Biol. Chem. 259:1984;10841-10844.
18. Doherty D.H., Doyle M.P., Curry S.R., Vali R.J., Fattor T.J., Olson J.S., Lemon D.D. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin [see comments]. Nat. Biotechnol. 16:1998;672-676.
19. Looker D., Abbott-Brown D., Cozart P., Durfee S., Hoffman S., Mathews A.J., Miller-Roehrich J., Shoemaker S., Trimble S., Fermi G., et al. A human recombinant haemoglobin designed for use as a blood substitute. Nature. 356:1992;258-260.
20. O'Donnell J.K., Martin M.J., Logan J.S., Kumar R. Production of human hemoglobin in transgenic swine: an approach to a blood substitute. Cancer Detect. Prev. 17:1993;307-312.
21. McGarrity M.J., Hsia J.C., Er S.S. Hemoglobin-based blood substitutes: characterization of five pyridoxal 5′-phosphate derivatives of hemoglobin. J. Chromatogr. 419:1987;37-50.
22. Everse J., Hsia N. The toxicities of native and modified hemoglobins. Free Radic. Biol. Med. 22:1997;1075-1099.
23. Rohlfs R.J., Winslow R.M., Vandegriff K.D., Magde M.D. Jr., Magde D., Gonzales M.L., Gonzales A., Chiu A., Bruner E. Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide. J. Biol. Chem. 273:1998;12128-12134.
24. Alayash A.I. Effects of intra- and intermolecular crosslinking on the free radical reactions of bovine hemoglobins. Free Radic. Biol. Med. 18:1995;295-301.
25. Motterlini R., Foresti R., Vandegriff K., Winslow R.M. The autoxidation of alpha alpha cross-linked hemoglobin: a possible role in the oxidative stress to endothelium. Artif. Cells Blood Substit. Immobil. Biotechnol. 23:1995;291-301.
26. Rogers M.S., Alayash A.I., Cashon R.E., Ryan B.B. Effects of polymerization on the oxygen carrying and redox properties of diaspirin cross-linked hemoglobin. Biochim. Biophys. Acta. 27:1995;135-142.
27. Svistunenko D.A., Patel R.P., Voloshchenko S.V., Wilson M.T. The globin-based free radical of ferryl hemoglobin is detected in normal human blood. J. Biol. Chem. 272:1997;7114-7121.
28. Vandegriff K.D., McCarthy M., Rohlfs R.J., Winslow R.M. Colloid osmotic properties of modified hemoglobins: chemically cross-linked versus polyethylene glycol surface-conjugated. Biophys. Chem. 69:1997;23-30.
29. Sehgal L.R., Gould S.A., Rosen A.L., Sehgal H.L., Moss G.S. Polymerized pyridoxylated hemoglobin: a red cell substitute with normal oxygen capacity. Surgery. 95:1984;433-438.
30. Gould S.A., Moss G.S. Clinical development of human polymerized hemoglobin as a blood substitute. World J. Surg. 20:1996;1200-1207.
31. Hein L.G., Albrecht M., Dworschak M., Frey L., Bruckner U.B. Long-term observation following traumatic-hemorrhagic shock in the dog: a comparison of crystalloidal vs. colloidal fluids. Circ. Shock. 26:1988;353-364.
32. Tsai A.G., Kerger H., Intaglietta M. Microcirculatory consequences of blood substitution with alpha-alpha-hemoglobin. Winslow R.M., Vandegriff K.D., Intaglietta M. Blood Substitutes: Physiological Basis of Efficacy. 1995;155-174 Birkhäuser, Boston.
33. R.M. Winslow, K.D. Vandegriff, M. Intaglietta, Advances in blood substitutes: industrial opportunities and medical challenges., Advances in blood substitutes; v. 3. Birkhäuser, Boston, 1997, pp. xiv, 336.
34. R.M. Winslow, K.D. Vandegriff, M. Intaglietta, Blood substitutes: physiological basis of efficacy, [Advances in blood substitutes; v. 1]. Birkhäuser, Boston, 1995, pp. x, 205.
35. Winslow R.M., Gonzales A., Gonzales M.L., Magde M., McCarthy M., Rohlfs R.J., Vandegriff K.D. Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model. J. Appl. Physiol. 85:1998;993-1003.
36. Simoni J., Feola M., Hartsell A., Simoni G. An improved blood substitute. In vivo evaluation of its renal effects. Asaio J. 43:1997;M714-M725.
37. Yang T., Horejsh D.R., Mahan K.J., Zaluzec E.J., Watson T.J., Gage D.A. Mapping cross-linking sites in modified proteins with mass spectrometry: an application to cross-linked hemoglobins. Anal. Biochem. 242:1996;55-63.
38. Snyder S.R., Welty E.V., Walder R.Y., Williams L.A., Walder J.A. HbXL99 alpha: a hemoglobin derivative that is cross-linked between the alpha subunits is useful as a blood substitute. Proc. Natl. Acad. Sci. USA. 84:1987;7280-7284.
39. Chatterjee R., Welty E.V., Walder R.Y., Pruitt S.L., Rogers P.H., Arnone A., Walder J.A. Isolation and characterization of a new hemoglobin derivative cross-linked between the alpha chains (lysine 99 alpha 1-lysine 99 alpha 2). J. Biol. Chem. 261:1986;9929-9937.
40. Przybelski R.J., Daily E.K., Kisicki J.C., Mattia-Goldberg C., Bounds M.J., Colburn W.A. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit. Care Med. 24:1996;1993-2000.
41. Nelson D., Hai T., Srnak A., Ebeling A., Kunas G., Catarello J., Burhop K. Synthesis and properties of polymerized, diaspirin cross-linked hemoglobins. Biomater. Artif. Cells Immobil. Biotechnol. 20:1992;253-258.
42. Gulati A., Sharma A.C., Singh G. Role of endothelin in the cardiovascular effects of diaspirin crosslinked and stroma reduced hemoglobin. Crit. Care Med. 24:1996;137-147.
43. Sharma A.C., Gulati A. Yohimbine modulates diaspirin crosslinked hemoglobin-induced systemic hemodynamics and regional circulatory effects [see comments]. Crit. Care Med. 23:1995;874-884.
44. Sharma A.C., Singh G., Gulati A. Role of NO mechanism in cardiovascular effects of diaspirin cross-linked hemoglobin in anesthetized rats. Am. J. Physiol. 269:1995;H1379-H1388.
45. Gulati A., Rebello S. Diaspirin cross-linked hemoglobin (DCLHB): involvement of adrenergic mechanisms in the pressor effect. Artif. Cells Blood Substit. Immobil. Biotechnol. 22:1994;603-612.
46. Katsuyama S.S., Cole D.J., Drummond J.C., Bradley K. Nitric oxide mediates the hypertensive response to a modified hemoglobin solution (DCLHb) in rats. Artif. Cells Blood Substit. Immobil. Biotechnol. 22:1994;1-7.
47. Gulati A., Sharma A.C. Prazosin blocks the pressor but not the regional circulatory effects of diaspirin crosslinked hemoglobin. Life Sci. 55:1994;121-130.
48. Bilello K., Schultz S., Powell C., Jaffin J., Cole F., Malcolm D. Diaspirin crosslinked hemoglobin (DCLHb): control of pressor effect with anti-hypertensive agents. Artif. Cells Blood Substit. Immobil. Biotechnol. 22:1994;819-825.
49. Abassi Z., Kotob S., Pieruzzi F., Abouassali M., Keiser H.R., Fratantoni J.C., Alayash A.I. Effects of polymerization on the hypertensive action of diaspirin cross-linked hemoglobin in rats [see comments]. J. Lab. Clin. Med. 129:1997;603-610.
50. Zhang Q., Olsen K.W. The modification of hemoglobin by a long crosslinking reagent: bis(3,5-dibromosalicyl) sebacate. Biochem. Biophys. Res. Commun. 203:1994;1463-1470.
51. Huang H., Olsen K.W. Thermal stabilities of hemoglobins crosslinked with different length reagents. Artif. Cells Blood Substit. Immobil. Biotechnol. 22:1994;719-724.
52. Brouwer M., Cashon R., Bonaventura J. Carbodiimide-mediated coupling of benzenepentacarboxylate to human hemoglobin: structural and functional consequences. Biomater. Artif. Cells Immobil. Biotechnol. 20:1992;323-326.
53. Faivre B., Menu P., Labrude P., Grandgeorge M., Vigneron C., Dellacherie E. A potential blood substitute from carboxylic dextran and oxyhemoglobin. II. Physicochemical and physiological assessments. Preliminary results on guinea pig. Biomater. Artif. Cells Immobil. Biotechnol. 20:1992;597-600.
54. Menu P., Donner M., Faivre B., Labrude P., Vigneron C. In vitro effect of dextran-benzene-tetra-carboxylate hemoglobin on human blood rheological properties. Artif. Cells Blood Substit. Immobil. Biotechnol. 23:1995;319-330.
55. Prouchayret F., Dellacherie E. Low oxygen affinity derivatives of human hemoglobin by fixation of polycarboxylic dextran to the oxyform. Biopolymers. 33:1993;1803-1809.
56. Michelson, Biochim. Biophys. Acta 91 (1964).
57. Shimomura S., Fukui T. Characterization of the pyridoxal phosphate site in glycogen phosphorylase b from rabbit muscle. Biochemistry. 17:1978;5359-5367.
58. Keipert P.E., Adeniran A.J., Kwong S., Benesch R.E. Functional properties of a new crosslinked hemoglobin designed for use as a red cell substitute [see comments]. Transfusion. 29:1989;768-773.
59. Pocker A. Synthesis of 2-nor-2-formylpyridoxal 5′-phosphate, a bifunctional reagent specific for the cofactor site in proteins. J. Org. Chem. 38:1973;4295-4299.
60. Berbers G.A., Bleeker W.K., Stekkinger P., Agterberg J., Rigter G., Bakker J.C. Biophysical characteristics of hemoglobin intramolecularly cross-linked and polymerized. J. Lab. Clin. Med. 117:1991;157-165.
61. Bleeker W.K., van der Plas J., Agterberg J., Rigter G., Bakker J.C. Prolonged vascular retention of a hemoglobin solution modified by cross-linking with 2-nor-2-formylpyridoxal 5′-phosphate. J. Lab. Clin. Med. 108:1986;448-455.
62. Bleeker W.K., van der Plas J., Feitsma R.I., Agterberg J., Rigter G., de Vries-van Rossen A., Pauwels E.K., Bakker J.C. In vivo distribution and elimination of hemoglobin modified by intramolecular cross-linking with 2-nor-2-formylpyridoxal 5′-phosphate. J. Lab. Clin. Med. 113:1989;151-161.
63. Hess J.R., MacDonald V.W., Brinkley W.W. Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J. Appl. Physiol. 74:1993;1769-1778.
64. Keipert P.E., Gonzales A., Gomez C.L., MacDonald V.W., Hess J.R., Winslow R.M. Acute changes in systemic blood pressure and urine output of conscious rats following exchange transfusion with diaspirin-crosslinked hemoglobin solution. Transfusion. 33:1993;701-708.
65. Keipert P.E., Gomez C.L., Gonzales A., MacDonald V.W., Hess J.R., Winslow R.M. Diaspirin cross-linked hemoglobin: tissue distribution and long-term excretion after exchange transfusion. J. Lab. Clin. Med. 123:1994;701-711.
66. Gould S.A., Moore E.E., Hoyt D.B., Burch J.M., Haenel J.B., Garcia J., DeWoskin R., Moss G.S. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery [see comments]. J. Am. Coll. Surg. 187:1998;113-120.
67. Kuznetsova N.P., Gudkin L.R., Mishaeva R.N., Stragovich L.M., Bistrova I.M., Selivanov E.A. Synthesis, physico-chemical and biological properties of crosslinked modified hemoglobin. Artif. Cells Blood Substit. Immobil. Biotechnol. 26:1998;213-222.
68. Marks D.H., Moore G.L., Medina F., Boswell G., Zieske L.R., Bolin R.B., Zegna A.I. Optimization and synthesis of pyridoxalated polymerized stroma-free hemoglobin solution. Mil. Med. 153:1988;44-49.
69. Kothe N., Eichentopf B., Bonhard K. Characterization of a modified, stroma-free hemoglobin solution as an oxygen-carrying plasma substitute. Surg. Gynecol. Obstet. 161:1985;563-569.
70. Bleeker W.K., Berbers G.A., den Boer P.J., Agterberg J., Rigter G., Bakker J.C. Effect of polymerization on clearance and degradation of free hemoglobin. Biomater. Artif. Cells Immobil. Biotechnol. 20:1992;747-750.
71. Bleeker W.K., Berbers G.A., den Boer P.J., Agterberg J., Rigter G., Bakker J.C. Hemorrhagic disorders after administration of glutaraldehyde-polymerized hemoglobin. Winslow R.M., Vandegriff K.D., Intaglietta M. Blood Substitutes: New Challenges. 1996;112 Birkhäuser, Boston.
72. Lee R., Vlahakes G.J., Svizzero T.A., Neya K. Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. J. Appl. Physiol. 79:1995;236-242.
73. D. Pliura, L.T. Wong, S.S. Er, Selective crosslinking of hemoglobin by oxidized, ring-opened saccharides, U.S. Pat. No. 5,532,352, 1996.
74. Conover C.D., Gilbert C.W., Shum K.L., Shorr R.G. The impact of polyethylene glycol conjugation on bovine hemoglobin's circulatory half-life and renal effects in a rabbit top-loaded transfusion model. Artif. Organs. 21:1997;907-915.
75. Bradley R., Sloshberg S., Nho K., Czuba B., Szesko D., Shorr R. Production of PEG-modified bovine hemoglobin: economics and feasibility. Artif. Cells Blood Substit. Immobil. Biotechnol. 22:1994;657-667.
76. Linberg R., Conover C.D., Shum K.L., Shorr R.G. Increased tissue oxygenation and enhanced radiation sensitivity of solid tumors in rodents following polyethylene glycol conjugated bovine hemoglobin administration. In Vivo. 12:1998;167-173.
77. J.C. Hsia, Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute, U.S. Pat. No. 5,591,710, 1997.
78. D'Agnillo F., Chang T.M. Cross-linked hemoglobin-superoxide dismutase-catalase scavenges oxygen-derived free radicals and prevents methemoglobin formation and iron release. Biomater. Artif. Cells Immobil. Biotechnol. 21:1993;609-621.
79. Doyle M.P., Apostol I., Kerwin B.A. Glutaraldehyde modification of recombinant human hemoglobin alters its hemodynamic properties. J. Biol. Chem. 274:1999;2583-2591.
80. Marquardt D.A., Epp J.K., Vincelette J., Suniga M., Dotle M.P., Anthony-Cahill S.J. Characterization of a 260 kDa Tetrahemoglobin obtained by Chemical Crosslinking of a Cysteine-Containing Dihemoglobin. VII International Symposium on Blood Substitutes. Montreal, Quebec, Canada, 1997. Abstracts. 1:1997;1-144.
81. D.D. Lemon, Design of new recombinant hemoglobins for oxygen carrying therapeutics. ASAIO 45th Anniversary Meeting, 1999.
82. Gulati A. Recent advances in development of haemoglobin-based blood substitutes. Expert Opin. Invest. Drugs. 6:1997;1659-1669.
83. Alayash A.I., Ryan B.A., Fratantoni J.C., Bonaventura J., C B. Hemoglobin-based oxygen carriers (HBOCs): structural alterations that affect free radical generation. Biomater. Artif. Cells Immobil. Biotechnol. 20:1992;277-281.
84. MacDonald S.L., Pepper D.S. Hemo globin poly merization. Methods Enzymol. 231:1994;287-308.
85. Menu P., Faivre B., Labrude P., Grandgeorge M., Vigneron C. Possible importance of chromatographic purification position in a blood substitute elaboration process. Biomater. Artif. Cells Immobil. Biotechnol. 20:1992;443-445.
86. Conover C.D., Shorr R.G., Shum K.L., Gilbert C.W., Linberg R. Effect of polyethylene glycol conjugated bovine hemoglobin in both top-load and exchange transfusion rat models. Artif. Organs. 21:1997;1066-1075.
87. Sehgal L.R., Rosen A.L., Gould S.A., Sehgal H.L., Moss G.S. Preparation and in vitro characteristics of polymerized pyridoxylated hemoglobin. Transfusion. 23:1983;158-162.
88. Keipert P.E., Verosky M., Triner L. Plasma retention and metabolic fate of hemoglobin modified with an interdimeric covalent cross link. ASAIO Trans. 35:1989;153-159.
89. Bakker J.C., Berbers G.A., Bleeker W.K., den Boer P.J., Biessels P.T. Preparation and characterization of crosslinked and polymerized hemoglobin solutions. Biomater. Artif. Cells Immobil. Biotechnol. 20:1992;233-241.
90. Marini M.A., Moore G.L., Fishman R.M., Jessee R., Medina F., Snell S.M., Zegna A.I. A critical examination of the reaction of pyridoxal 5-phosphate with human hemoglobin Ao. Biopolymers. 28:1989;2071-2083.
91. Bush S., Marshall T., Spicuzza J., Nelson D. Diaspirin crosslinked hemoglobin (DCLHb): bioanalytical studies in swine. Artif. Cells Blood Substit. Immobil. Biotechnol. 22:1994;917-922.
92. Cole D.J., McKay L., Jacobsen W.K., Drummond J.C., Patel P.M. Effect of subarachnoid administration of alpha-alpha diaspirin crosslinked hemoglobin on cerebral blood flow in rats. Artif. Cells Blood Substit. Immobil. Biotechnol. 25:1997;95-104.
93. Hai T.T., Nelson D., Pereira D., Srnak A. Diaspirin crosslinked hemoglobin (DCLHb) polymerization. Artif. Cells Blood Substit. Immobil. Biotechnol. 22:1994;923-931.
94. Menu P., Mouelle P., Clerc Y., Labrude P., Vigneron C. Physico-chemical and pharmacological comparison of pyridoxylated hemoglobin bound to polyoxyethylene or polymerized by glutaraldehyde. Int. J. Artif. Organs. 14:1991;805-809.